CSE | OTC | FSE

novamentis life science

The Nova Mission

We’re a Canadian-based biotechnology company and global leader in psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. Our mission is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder and fragile X syndrome.

 

Our Holdings

novamentis biotech

Nova Mentis Biotech

Wholly owned subsidiary investigating medicinal psychedelics. Current focus indications: obesity, diabetes, liver disease (NASH)

Learn More


Pilz BioScience

Pilz Bioscience

Wholly owned subsidiary investigating medicinal psychedelics. Current focus indications: Autism Spectrum Disorder

Learn More

Nova Mentis Life Science
Stock Performance

CSE FSE

Nova Mentis Autism Clinical Study

 

Sign up to learn more

Latest News

Nova Mentis Appoints Dr. Stephen Glazer as Director and Chief Science Officer

Vancouver, British Columbia – July 15, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce the appointment of Dr. Stephen Glazer as Director, Chief Science Officer.

 

Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board

Vancouver, British Columbia – June 23, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has received Canadian approval for its North American autism clinical study.